Graft Versus Host Disease: Epidemiology Forecast to 2028

Price :
Published : Jan-2020
No. of Pages : 92

Graft Versus Host Disease: Epidemiology Forecast to 2028


GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.

GlobalData epidemiologists utilized historical HSCT data available through country-wide registry reports in the 7MM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, GlobalData epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.

The following data describes epidemiology of GvHD cases. In 2018, the 7MM had 18,408 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 22,428 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 2.18%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 7MM. In the 7MM, the diagnosed incident cases of aGvHD will increase from 9,786 cases in 2018 to 11,925 cases in 2028, at an Annual Growth Rate (AGR) of 2.19% per year, and the diagnosed incident cases of cGvHD will increase from 8,622 cases in 2018 to 10,503 cases in 2028, at an AGR of 2.18% per year.


– Graft Versus Host Disease (GvHD) Epidemiology Report provides an overview of the risk factors and global trends of GvHD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of first allogeneic Hematopoietic stem cell transplantation (HSCT), acute GvHD (aGvHD), and chronic GvHD (cGvHD); diagnosed three-year prevalent cases of aGvHD and cGvHD; and diagnosed incident cases of aGvHD and cGvHD by grade and severity respectively. Additionally, 100-day mortality in aGvHD and one-year mortality cases in cGvHD is also included in this report.
– The GvHD Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GvHD Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global GvHD market.
– Quantify patient populations in the global GvHD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the aGvHD grades and cGvHD severity stages that present the best opportunities for GvHD therapeutics in each of the markets covered.
– Understand magnitude GvHD market by mortality rates and three-year prevalent cases.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Teleradiology Market by Products & Services (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers & Laboratories), COVID-1 Impact – Forecast to 2025

“Dearth of skilled radiologists & need for faster and improved diagnosis are driving market growth” The teleradiology market is expected to reach USD 22.8 billion by 2025 from USD 7.9 billion in 2020, at a CAGR of 23.5% during the forecast period of 2020 to 2025. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for teleradiology services. The growth of this market is mainly attributed to the rising geriatric population and the subsequent increase in the prevalence of associated diseases, the increasing adoption of cloud-based solutions, and the benefits offered by teleradiology and a dearth of skilled radiologists. However, declining reimbursements and increasing regulatory burden in the US and data breaching of imaging report hampered market gr......

Coronavirus Disease 2019 – Epidemiology Analysis and Forecast – June 2020

Coronavirus Disease 2019 - Epidemiology Analysis and Forecast - June 2020 Summary The pandemic's epicenters have shifted to Latin America, India, Pakistan, and South Africa. COVID-19 is mainly affecting the dense populous and poorer regions of these countries. As a result, the global daily confirmed cases are increasing at a higher pace than before. The US continues to be the most affected country globally, reaching close to 2.5 million cases. The US reported the highest number of new daily cases on 26 June since the start of the pandemic. Chile moves up ahead of Spain. Brazil has now reported more than 1 million total confirmed cases of COVID-19. Mexico is now ranked 11th among the top most affected countries. The report covers current epidemiology situation, forecast, and analysis ......

Amyloidosis – Epidemiology Forecast to 2029

Amyloidosis - Epidemiology Forecast to 2029 Summary Amyloidosis is a rare disease characterized by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alters the normal functions of the tissues in the organs (Holmes et al., 2019; Mayo Clinic, 2020). Amyloid is not normally found in the body, but it can be formed from several different types of protein and interferes with the organs' normal function. Organs that may be affected by amyloidosis include the heart, kidneys, liver, spleen, nervous system, and digestive tract (Mayo Clinic, 2020). The signs and symptoms of amyloidosis include dizziness, fluid retention, fatigue, fainting, an enlarged tongue, low blood pressure, and shortness of breath (Mayo Clinic, 2020; Stanford Health Care, 2020). There ar......

Transthyretin Amyloidosis – Global Drug Forecast and Market Analysis to 2029

Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029 Summary Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis diagnoses are made later in life, with the average patient aged 65 at diagnosis. Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein an......

Impact on Publicly Traded Bio/Pharma Companies – Coronavirus Disease (COVID-19) 2019 Impact Report

Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Scope - This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.......

Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029 Summary Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019 to $5.1B in 2029 at a compound annual growth rate (CAGR) of 13.6%. This dramatic growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the......

Acute Myeloid Leukemia – Epidemiology Forecast to 2029

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Gr......

Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) – Global Forecast to 2025

 “The aseptic sampling market is projected to grow at a CAGR of 12.4% during the forecast period (2020–2025).” The global aseptic sampling market size is projected to reach USD 474 million by 2025 from USD 264 million in 2020, at a CAGR of 12.4%. The growth of this market is driven majorly by factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities. On the other hand, issues related to leachables and extractable from single-use products are restraining market growth. “By type, the manual aseptic sampling segment is expected to grow at the highest CAGR during the forecast period.” Based on type, the aseptic sampling market is segmented into manual aseptic......

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. Scope The report includes 10 Influencers - - Eight therapy areas: Cardiovascular, Metabolic Disord......

Digital Biomarkers – Coronavirus Disease 2019 (COVID-19) Case Study

Digital Biomarkers - Coronavirus Disease 2019 (COVID-19) Case Study Summary The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond. Key Highlights - Digital biomarkers are an important addition to the armamentarium of tools supporting pa......
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy